Retinal scan

Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
Tuesday, March 19, 2024
Cloud, OSA, APLS, ASRS, Environment, Patient, Public, Inflammation, News, LLP, Retinal scan, DOJ, Complaint, CMI, Retinal vasculitis, EPA, Justice, Society, Retina, Safety, Paratriathlon, Physician, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Cummins, Inc. against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Cummins, Inc. against certain of its officers and directors.
  • Johnson Fistel LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Inspire Medical Systems, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Applied Digital Corporation against certain of its officers and directors.

Investigation Alert Driven Brands Holdings, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
Tuesday, March 5, 2024
Cloud, Complaint, SAN, ASRS, DRVN, APLS, OSA, Physician, Inflammation, Retina, News, Holding, Retinal scan, Safety, Society, Patient, Retinal vasculitis, LLP, Paratriathlon, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Driven Brands Holdings, Inc. against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Driven Brands Holdings, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Inspire Medical Systems, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Applied Digital Corporation against certain of its officers and directors.

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
Tuesday, January 16, 2024
Transfer, Cloud, Patient, Bureau, LLP, Electronic Fund Transfer Act, Knowledge, Retinal vasculitis, ASRS, Retinal scan, Society, Consumer, KeyBank, Paratriathlon, Safety, Inflammation, NII, ACI, Retina, Complaint, News, Physician

Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • If you have continuously owned Apellis Pharmaceuticals shares since before January 28, 2021, submit your information below:
    Recently a class action lawsuit was filed against the company.
  • Johnson Fistel, LLP is investigating potential claims on behalf of KeyCorp against certain of its officers and directors.
  • Due to weaknesses in its information security practices, ACI caused the erroneous bill payment orders to be sent to consumers’ banks for processing.

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
Thursday, December 14, 2023
Transfer, Cloud, Retinal vasculitis, KeyBank, Physician, LLP, ASRS, Complaint, Retinal scan, Society, Consumer, News, Inflammation, ACI, Electronic Fund Transfer Act, Bureau, Knowledge, NII, Patient, Safety, Paratriathlon, Retina

Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • If you have continuously owned Apellis Pharmaceuticals shares since before January 28, 2021, submit your information below:
    Recently a class action lawsuit was filed against the company.
  • Johnson Fistel, LLP is investigating potential claims on behalf of KeyCorp against certain of its officers and directors.
  • Due to weaknesses in its information security practices, ACI caused the erroneous bill payment orders to be sent to consumers’ banks for processing.

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
Wednesday, December 6, 2023
Transfer, Cloud, Retinal vasculitis, KeyBank, Physician, LLP, ASRS, Complaint, Retinal scan, Society, Consumer, News, Inflammation, ACI, Electronic Fund Transfer Act, Bureau, Knowledge, NII, Patient, Safety, Paratriathlon, Retina

Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • If you have continuously owned Apellis Pharmaceuticals shares since before January 28, 2021, submit your information below:
    Recently a class action lawsuit was filed against the company.
  • Johnson Fistel, LLP is investigating potential claims on behalf of KeyCorp against certain of its officers and directors.
  • Due to weaknesses in its information security practices, ACI caused the erroneous bill payment orders to be sent to consumers’ banks for processing.

APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, November 3, 2023
Wedbush Securities, Food, Retinal scan, Physician, ASRS, Inflammation, Telephone, News, Geographic atrophy, Injection, Regulation of tobacco by the U.S. Food and Drug Administration, Society, P.C, Retinal vasculitis, Vasculitis, Complaint, Risk, Clinical trial, GA, Paratriathlon, Safety, Autoimmunity, Patient, Retina, First, APLS, Cryptocurrency, Pharmaceutical industry

Our investigation concerns whether the board of directors of Apellis have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Apellis have breached their fiduciary duties to the company.
  • Apellis is a commercial-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
  • SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system.
  • Apellis also stated that the company is evaluating an eighth reported event of retinal vasculitis, which Apellis had not yet confirmed.

Investigation Alert Apellis Pharmaceuticals, KeyCorp, RTX Corporation, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
Monday, October 30, 2023
Cloud, RTX, GTF, Complaint, NYSE, Retinal scan, Physician, ASRS, News, NII, Inflammation, Society, KeyBank, Retinal vasculitis, LLP, Raytheon Technologies, Paratriathlon, Safety, Patient, Retina, Pharmaceutical industry, Cryptocurrency, Insurance, Tobacco

Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • If you have continuously owned Apellis Pharmaceuticals shares since before January 28, 2021, submit your information below:
    Recently a class action lawsuit was filed against the company.
  • Johnson Fistel, LLP is investigating potential claims on behalf of KeyCorp against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Applied Digital Corporation against certain of its officers and directors.

APELLIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, September 30, 2023
Legal, Professional Services, Retinal scan, Retina, Injection, P.C, Autoimmunity, APLS, Telephone, Retinal vasculitis, Clinical trial, Geographic atrophy, Jeanne Eagels, Vasculitis, Paratriathlon, Risk, GA, Inflammation, Person, First, Wedbush Securities, District court, Patient, Physician, Complaint, Court, Regulation of tobacco by the U.S. Food and Drug Administration, Society, News, Food, ASRS, Safety, Pharmaceutical industry

Investors have until October 2, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until October 2, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Apellis is a commercial-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
  • SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system.
  • Apellis also stated that the company is evaluating an eighth reported event of retinal vasculitis, which Apellis had not yet confirmed.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, September 28, 2023
EOS, Retinal scan, Retina, Injection, P.C, RTX, Autoimmunity, APLS, Retinal vasculitis, Clinical trial, Geographic atrophy, Vasculitis, Paratriathlon, Risk, GA, Inflammation, DOE, Primary energy, LPO, Kilowatt-hour, First, Wedbush Securities, Patient, Physician, Complaint, Defendant, GTF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, News, Food, ASRS, Safety, Society, Security (finance), Audit, Cryptocurrency, Pharmaceutical industry, Eos

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • On this news, the price of RTX shares declined by more than 10%, damaging investors.
  • Apellis also stated that the company is evaluating an eighth reported event of retinal vasculitis, which Apellis had not yet confirmed.
  • For more information on the Apellis class action go to: https://bespc.com/cases/APLS

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Apellis, Party City, and Hayward and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, September 23, 2023
Retinal scan, Retina, Injection, P.C, LLP, Autoimmunity, APLS, Chapter 11, Title 11, United States Code, Inflammation, Retinal vasculitis, Clinical trial, Geographic atrophy, Vasculitis, Paratriathlon, Risk, GA, First, Wedbush Securities, Patient, Physician, Nature, III, Complaint, OTC, Party, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, NYSE, Society, Food, ASRS, Safety, Ernst & Young, Pharmaceutical industry, Cryptocurrency, Audit, Hayward, Party City

SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system.

Key Points: 
  • SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system.
  • For more information on the Apellis class action go to: https://bespc.com/cases/APLS
    After trading on January 17, 2023, Party City filed for bankruptcy protection under Chapter 11.
  • As a result, the price of Hayward Holdings common stock fell nearly 24%, damaging investors.
  • For more information on the Hayward class action go to: https://bespc.com/cases/HAYW